

## Press Release

### **New Mymetics data regarding cold chain independent virosome based vaccines to be presented at AAPS in Washington, D.C.**


- *Poster presentation showing retention of structural integrity and good immunogenicity of spray dried virosome-based vaccine stored at different temperatures and administered as a nasal powder*
- *Poster presentation at AAPS – Washington, D.C., USA, Tuesday November 6<sup>th</sup>, 2018*

**Epalinges, Switzerland, 11 October 2018** – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announces that new data will be presented by Mymetics' partner, Upperton Ltd., at the American Association of Pharmaceutical Scientists Annual Meeting in Washington, D.C., on November 5<sup>th</sup>-7<sup>th</sup>, 2018.

Since 2015, Mymetics has been leading a consortium to develop thermostable and cold-chain independent virosome-based vaccines. The project, named MACIVIVA, is funded as part of Horizon 2020, the European Union research and innovation framework program and by the Swiss State Secretariat for Education, Research and Innovation (SERI), and has a total grant value of €8.4 million. With the MACIVIVA project, Mymetics has brought together the leading contract manufacturers and the relevant expertise for spray drying, freeze drying and analytical techniques from the pharmaceutical industry.

The poster with the title “Developing Cold Chain Independent Vaccines - Spray-drying of Virosomes to Produce Dry Powder Formulations” will be presented by Dr. Richard Johnson, the CEO of Upperton Ltd, on Tuesday the 6<sup>th</sup> of November. Dr. Johnson will discuss that the successful spray drying of the Mymetics' HIV virosome-based candidate vaccine. The spray dried powder formulation stored at 4°C (40°F) or 40°C (104°F) maintained its structural integrity, while the liquid formulation showed strong structural degradation at 40°C (104°F). Further, a pre-clinical in vivo study confirmed that the nasal delivery of spray dried virosomes was an effective, needle-free route for immunization, with levels of immune response comparative to that obtained by subcutaneous injection.

Upperton Pharma Solutions Ltd., based in Nottingham, the United Kingdom, has a long track record in overcoming complex spray drying formulation challenges in the pharmaceutical industry and has an R&D and pilot plant facility for the manufacturing from small scale to clinical batches of spray dried drug substances and products.

The MACIVIVA project will end early November 2018 and may receive up to €5.3 million funding from the European Union's Horizon 2020 research and innovation program under Grant Agreement No 646122. 

#### **About Mymetics**

Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, malaria, Chikungunya and the RSV vaccine and a collaborative project in the field of allergy Immunotherapy with Anergis SA.

Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. For further information, please visit [www.mymetics.com](http://www.mymetics.com).

**CONTACTS:****Mymetics Corporation**

Ronald Kempers

CEO

Tel: +41 21 653 4535

**Forward looking statements**

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.